Advertisement
News
Subscribe to MDT Magazine News

Reportlinker Adds Europe ENT Devices Market Outlook to 2017

April 21, 2011 2:33 am | by Bio-Medicine.Org | Comments

NEW YORK, April 21, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Europe ENT Devices Market Outlook to 2017 http://www.reportlinker.com/p0333693/Europe-ENT-Devices-Market-Outlook-to-2017.html Europe ENT Devices Market Outlook to 2017...

TOPICS:

Reportlinker Adds Medical Equipment Annual Deals Analysis 2011

April 21, 2011 1:34 am | by Bio-Medicine.Org | Comments

NEW YORK, April 21, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Medical Equipment Annual Deals Analysis 2011 http://www.reportlinker.com/p0180789/Medical-Equipment-Annual-Deals-Analysis-2011.html Medical Equipment Annual Deals...

TOPICS:

Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)

April 20, 2011 9:36 pm | by Bio-Medicine.Org | Comments

THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral...

TOPICS:
Advertisement

Summary Box: Amgen reports 1Q financial results(2)

April 20, 2011 3:46 pm | by The Associated Press | Comments

FINANCIAL RESULTS: Amgen Inc. said its profit fell 4 percent on higher costs, but adjusted profit and revenue topped Wall Street expectations.COSTS: The higher costs came mainly from marketing for the company's newly launched bone drugs, called Prolia and Xgeva, and for shifting three products to...

Summary Box: Amgen reports 1Q financial results

April 20, 2011 3:45 pm | Comments

FINANCIAL RESULTS: Amgen Inc. said its profit fell 4 percent on higher costs, but adjusted profit and revenue topped Wall Street expectations.COSTS: The higher costs came mainly from marketing for the company's newly launched bone drugs, called Prolia and Xgeva, and for shifting three products to...

Dynavax to get $6 million payment from Glaxo

April 20, 2011 1:45 pm | by The Associated Press | Comments

Biotechnology company Dynavax Technologies Corp. said Wednesday it will receive a $6 million milestone payment from partner GlaxoSmithKline after it started a study on a potential lupus drug.Dynavax started early-stage testing on DV1179. The Phase 1 clinical trial is aimed at testing safety and...

Boston Scientific Announces Results for First Quarter Ended March 31, 2011

April 20, 2011 1:33 pm | by Boston Scientific | Comments

NATICK, Mass., April 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and earnings per share (EPS) guidance

TOPICS:

Amgen 1Q profit falls 4 percent on higher costs

April 20, 2011 12:45 pm | by The Associated Press | Comments

Amgen Inc. says its first-quarter profit fell about 4 percent as it spent more on marketing, research and materials costs, but adjusted results topped Wall Street expectations.The biotechnology company, which makes cancer drugs and anemia treatments, says it earned nearly $1.13 billion, or...

Advertisement

ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011

April 20, 2011 12:35 pm | by Bio-Medicine.Org | Comments

EXTON, Pa., April 20, 2011 /- ViroPharma Incorporated's (Nasdaq: VPHM ) first quarter financial results for 2011 are expected to be released on Thursday, April 28, 2011 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00...

TOPICS:

Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories

April 20, 2011 11:36 am | by Bio-Medicine.Org | Comments

BUFFALO, N.Y., April 20, 2011 /-  Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian...

TOPICS:

Top Three Healthcare Supply Chain Executives Challenge Industry

April 20, 2011 11:32 am | by Bio-Medicine.Org | Comments

DALLAS, April 20, 2011 /- Senior executives from the top three healthcare organizations on Gartner's "The Healthcare Supply Chain Top 25 for 2010"* revealed strategies their companies leveraged to become industry supply chain leaders during this morning's keynote panel discussion at the...

TOPICS:

Consumer Information on: Valiant & #xae; Thoracic Stent Graft with the Captiva Delivery System - P100040

April 20, 2011 11:30 am | by U.S. Food & Drug Administration | Comments

The Valiant® Thoracic Stent Graft with the Captivia Delivery System is an endovascular stent graft2 and is used to repair fusiform aneurysms or saccular aneurysms/penetrating ulcers of the aorta3 in the chest. The Valiant® Thoracic Stent Graft is made...

TOPICS:

TSX-listed corporate dividends and distributions declared April 20, 2011

April 20, 2011 10:45 am | by The Associated Press | Comments

Dividends or distributions were declared or updated on the followed listed issues on the Toronto Stock Exchange on April 20, 2011.Accord Financial Corp. (TSX:ACD): $0.075. Payable Jun 01. Record May 16.Allied Properties Real Estate Invest Trust Un (TSX:AP.UN): $0.11. Payable May 16. Record Apr...

NanoViricides lands $5M from stock offering

April 20, 2011 10:37 am | by Mass High Tech: The Journal of New England Technology | Comments

NanoViricides Inc., a biotechnology firm in West Haven, Conn., has taken in $5 million through a stock offering under a shelf registration with Seaside 88 LP.

Summary Information for: Valiant & #xae; Thoracic Stent Graft with the Captiva Delivery System

April 20, 2011 10:30 am | by U.S. Food & Drug Administration | Comments

Labeling, Approval Order, and Summary of Safety and Effectiveness for Valiant® Thoracic Stent Graft with the Captiva Delivery System (P100040).

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading